ImmunoShield Therapeutics
Empowering cell therapies
Our Story
Enabling Cell Therapies
Immunoshield Therapeutics was founded in 2021 by Dr. Jessica Weaver and Oren Snir based on technology developed in Dr. Weaver's lab at Arizona State University. Our company seeks to enable allogeneic cell therapies in the absence of chronic systemic immunosuppression, which will increase the safety of cell therapies and vastly expand the eligible patient population.
We take a dual approach to solving this problem, with a cell macroencapsulation technology and a method to induce antigen-specific immune tolerance. Cell macroencapsulation enables the fabrication of retrievable cell-laden devices that are protected from direct recognition by the immune system. Antigen-specific immune tolerance protects cell therapies from indirect recognition by the immune system and eliminates the need for chronic systemic immunosuppression.
Cell Therapy Macroencapsulation
Hydrogel Injection Molding
Our Technology
Immune Tolerance
Tolerogenic Cell Therapy
Cell Therapy Macroencapsulation
Encapsulation can reduce, but not eliminate, the need for immunosuppressive drugs. The mission of our macroencapsulation strategy is to deliver highly functional encapsulated cells to the patient safely, retrievably, and easily.
What's different about ImmunoShield encapsulation?
The current leading methods for macroencapsulating cell products are costly, slow, and difficult to scale. Our process takes advantage of injection molding to encapsulate cells quickly and reliably into any clinically relevant geometry. Additionally, we perform extensive in silico modeling to optimize geometries and oxygen availability to encapsulated cells in order to give our devices greater function and engraftment in vivo compared to current leading clinical approaches. The versatility that our encapsulation approach offers in terms of scalability, geometry, and material versatility put it in a class of its own.
Easy
Fast
Safe
Indications and Pipeline
ImmunoShield Therapeutics is developing Cell Therapy Macroencapsulation and Tolerogenic Cell Therapy for a number of different indications, with a current focus around insulin secreting cell therapy.
Partnering
We are dedicated to partnering with other pharma and biotech leaders to expedite the development and delivery of macro-encapsulated cell therapies to patients.
Team
Jessica Weaver, PhD, Chief Scientific Officer.
Dr. Jessica Weaver is an Assistant Professor of Biomedical Engineering at Arizona State University. Dr. Weaver has 15 years of experience in cell transplantation and biomaterial development which led to the technology platforms licensed by ImmunoShield Therapeutics.
Matthew Becker, PhD, Chief Executive Officer.
Dr. Matthew Becker obtained his PhD from the University of Florida and has expertise in biomaterials and immune engineering technology platforms.
Oren Snir, JD MBA, Chief Operating Officer.
Oren Snir obtained his JD and MBA from Georgia State University and previously worked as an associate at Alston & Bird, LLP in data privacy and technology transactions.
Contact Us
Contact us for questions or info
info@immunoshieldtherapeutics.com
+1 480-788-6717